GlobalData on MSN7d
Allurion’s weight loss balloon back on French market
Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...
TMCnet1d
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...
MassDevice8d
Allurion relaunches weight loss balloon in France
Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...
BioWorld6d
Allurion cleared to resume sale of swallowable gastric balloon in France
Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...
Business Wire8d
Allurion Relaunches in France
The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com. Forward ...